Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross(South Australia Pathology), Timothy P. Hughes(South Australia Pathology), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Cassandra Slader(Novartis (Australia)), Anthony K. Mills(Princess Alexandra Hospital), Jarrad M. Goyne(South Australia Pathology), John F. Seymour(The Royal Melbourne Hospital), Andrew Grigg(The Royal Melbourne Hospital), Anthony P. Schwarer(The Alfred Hospital), Junia V. Melo(Hammersmith Hospital), Robin Filshie(St Vincent's Hospital Melbourne), David T Yeung(South Australia Pathology), Phuong Dang(South Australia Pathology), Susan Branford(Centre for Cancer Biology)
Cited by 705
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k